On October 13, 2020, the Focused Ultrasound Foundation and the Society for Neuro-Oncology (SNO) hosted a webinar on ultrasound-mediated blood-brain barrier disruption (BBBD).
Multiple clinical trials are ongoing or planned to investigate this rapidly developing approach to enhance small molecule, antibody, and cell delivery to brain tumors. This webinar brough togbether the pharmaceutical and biotech companies that are advancing this technology with investigators to provide an update on opportunities and challenges for using ultrasound BBBD to deliver therapeutics to brain tumor patients.
Five brief presentations by experts across the field were followed by a Q&A discussion.
Gelareh Zadeh, MD, PhD President, Society for Neuro-Oncology
Suzanne LeBlang, MD Director of Clinical Relationships, Focused Ultrasound Foundation
Panelists & Topics
Overview on the Use of Ultrasound for the Treatment of Glioma John de Groot, MD Professor, University of Texas MD Anderson Cancer Center
Focused Ultrasound Modulation of the Blood-Brain Barrier: Basic Principles and Technological Advances Kullervo Hynynen, MSc, PhD Senior Scientist, Sunnybrook Health Sciences Centre
Transcranial MR-Guided Focused Ultrasound in Neuro-Oncology: Proof-of-Concept and Experience in Early Phase Human Trials Nir Lipsman, MD, PhD, FRCSC Neurosurgeon and Scientist, Sunnybrook Health Sciences Centre
Clinical Effectiveness of Targeted and Transient Blood-Brain Barrier Opening via Neuronavigation-Guided Focused Ultrasound for Brain Tumors Kuo-Chen Wei, MD Neurosurgeon and Scientist, Chang Gung Memorial Hospital
The Use of Skull Implantable Ultrasound for Delivery of Paclitaxel for Glioblastoma Adam Sonabend, MD Assistant Professor of Neurological Surgery, Northwestern University, Feinberg School of Medicine
